Clinical OMICS

JAN-FEB 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/926715

Contents of this Issue

Navigation

Page 40 of 51

www.clinicalomics.com January/February 2018 Clinical OMICs 39 New Products Collection and Preservation of Urine Sample for DNA Preservation NextCollect urine collection and DNA preservation kit is now available, for research use only, to clinical research laboratories and pharmaceutical customers. NextCollect accommodates up to 250 mL of volume in its urine collection cup with a built-in de- livery of a preservative fluid in the collection cup lid to maximize the amount of cfDNA collected in each urine sample, while mini- mizing total DNA degradation during transport and storage. The product is designed for high-throughput lab processing with the ability to fit directly into standard centrifuge systems for initial specimen DNA separation requirements. The company plans to make its DNA Isolation Buffer Kits available in early 2018 to com- plement the NextCollect collection applications. These kits sup- port the isolation of pre- and post-renal cell-free DNA and RNA, using the methods developed with the Trovera ctDNA tests. Trovagene www.trovagene.com DNA Amplification Using cfDNA TruePrime is an apoptotic cell-free DNA amplification kit, launched under the Expedeon brand, which enables accurate DNA amplification using cell–free DNA (cfDNA) obtained from plasma, serum, urine, cerebrospinal fluid (CSF), or many other bodily fluids. The TruePrime kit uses a novel multiple displace- ment amplification method to overcome common limitations with the analysis of bodily fluid for cfDNA analysis. By expo- nentially amplifying cfDNA derived from apoptosis, the kits provide users with excellent sensitivity, error-free amplification in high yields and a streamlined workflow for reduced hands- on time. SYGNIS AG www.sygnis.com New Fusions Added to Lung Cancer Testing Panel Paradigm Cancer Diagnostic (PCDx) lung cancer testing panels were recently expanded to also include 17 fusions, as well as EGFR and MET skipping events. The fusions include: ALK, AXL, BRAF, CCND1, FGFR1, FGFR2, FGFR3, MET, NGR1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, ROS1, and THADA. The fusion panel may also be ordered as an add-on for any PCDx patients for stan- dard five-day turnaround. Paradigm uses anchored PCR technol- ogy on RNA to detect known and novel fusions with high sensi- tivity using a tissue requirement of 4% or greater tumor content in a single core needle biopsy or fine needle aspirate. PCDx is a clinical-grade comprehensive sequencing test that covers DNA, RNA, fusions, and immunohistochemistry and interrogates the most actionable targets with a 5,000x average depth of cover- age and delivers a report in five business days using the latest evidence with associations including associations to up to 87 different FDA approved therapies and 19 combinations. Paradigm Diagnostics www.paradigmdx.com 74-Gene NGS Research Panel for Hematological Malignancies The Ion Torrent Oncomine Myeloid Research Assay is a new, tar- geted next-generation se- quencing (NGS) research panel for simultaneous analysis of 74 relevant genes. It allows interroga- tion of DNA mutations, RNA fusion transcripts, and gene expres- sion levels associated with myeloid cancers in a single run, yield- ing results in two to three days. The assay is designed to analyze 40 DNA genes, 29 fusion driver genes, and five gene expression levels associated with several myeloid cancers, including: • acute myeloid leukemia (AML) • myeloid dysplastic syndrome (MDS) • myeloproliferative neoplasm (MPN) • chronic myeloid leukemia (CML) • chronic myelomonocytic leukemia (CMML) • juvenile myelomonocytic leukemia (JMML) The assay workflow is simplified with the Ion Chef System for library preparation. In addition, access to the Oncomine Knowl- edge Reporter allows users to link variants to relevant labels, guidelines and global clinical trials. Thermo Fisher Scientific www.thermofisher.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2018